Suzhou Immunofoco Biotechnology Co., Ltd
Clinical trials sponsored by Suzhou Immunofoco Biotechnology Co., Ltd, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Engineered immune cells take on stomach cancer in Late-Stage trial Results expected May 2027 (estimated)
- Can engineered cells beat blood cancers that Won't quit? Results expected Sep 2027 (estimated)
-
New CAR-T therapy IMV102 tested in Hard-to-Treat myeloma
Disease control Recruiting nowThis early-phase trial is testing a new treatment called IMV102 for people with relapsed/refractory multiple myeloma, a type of blood cancer that has not responded to at least three prior therapies. IMV102 is a personalized therapy made from the patient's own immune cells (CAR-T …
Early phase 1 • Sponsor: Suzhou Immunofoco Biotechnology Co., Ltd • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New hope for tough lymphoma: experimental drug IMV101 enters human testing
Disease control Recruiting nowThis early-phase study tests a new drug called IMV101 in 30 adults whose B-cell non-Hodgkin lymphoma has returned or not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants receive the …
Early phase 1 • Sponsor: Suzhou Immunofoco Biotechnology Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Engineered immune cells take on stomach cancer in Late-Stage trial
Disease control Recruiting nowThis phase 3 trial tests a new treatment called IMC002, which uses a patient's own immune cells (CAR T-cells) engineered to target a protein called CLDN18.2 found on some stomach cancer cells. The study includes 150 adults with advanced stomach cancer that has not responded to at…
Phase 3 • Sponsor: Suzhou Immunofoco Biotechnology Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC